BenevolentAI
ben phase clinical study designed to demonstrate in mild moderate atopic dermatitis study design safety efficacy study efficacy outcomes recruitment completed end of patients for ben vehicle patients inclusion criteria mild moderate viga itch atopic dermatitis affecting of treatable skin years dosing day medication washout followed by day placebo run in prior to dosing ben or placebo vehicle applied twice daily to treatable skin up to days on treatment powered itch change from in the pruritus worst itch over hours and current itch time to itch reduction fraction of patients achieving itch reduction in change from in score fraction of patients achieving improvement in score change from in affected by in treated area change from in viga quality of life change from in poem change from in change from in change from in sleep | BenevolentAI
Company
Deck Type
Deck date
March 2023
Slide
17 of 38
Related slides by other companies
Investor Day
June 2022
Results
August 2022
Investor Presentation
July 2023
Investor Presentation
February 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io